VEGF Expression and Cervical Cancer Treatment Response
Author Information
Author(s): Choi Chel Hun, Song Sang Yong, Choi Jung-Joo, Ae Park Young, Kang Heeseok, Kim Tae-Joong, Lee Jeong-Won, Kim Byoung-Gie, Lee Je-Ho, Bae Duk-Soo
Primary Institution: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
Hypothesis
Does VEGF expression predict the response to neoadjuvant chemotherapy in patients with bulky cervical carcinoma?
Conclusion
VEGF expression assessment can help identify cervical cancer patients who are less likely to respond to neoadjuvant chemotherapy.
Supporting Evidence
- 51.7% of patients were VEGF-positive.
- 27.6% of patients showed a complete or optimal response to chemotherapy.
- VEGF positivity was an independent predictor for poor response to treatment.
Takeaway
This study found that patients with high VEGF levels are less likely to respond well to chemotherapy for cervical cancer.
Methodology
VEGF expression was analyzed using immunohistochemistry on pre-treatment cervical biopsy tissues from 29 patients.
Potential Biases
Potential bias due to the selection of patients and the single-center study design.
Limitations
The study had a small sample size and focused only on a specific stage of cervical cancer.
Participant Demographics
Median age was 47 years, with 69% having stage IB2 disease.
Statistical Information
P-Value
0.009
Confidence Interval
1.15 – 112.58
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website